KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Receivables: 2009-2024

Historic Change in Receivables for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $201.7 million.

  • Sarepta Therapeutics' Change in Receivables fell 276.52% to -$131.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year decrease of 133.53%. This contributed to the annual value of $201.7 million for FY2024, which is 8.60% up from last year.
  • According to the latest figures from FY2024, Sarepta Therapeutics' Change in Receivables is $201.7 million, which was up 8.60% from $185.7 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Change in Receivables ranged from a high of $201.7 million in FY2024 and a low of $10.5 million during FY2020.
  • Its 3-year average for Change in Receivables is $149.7 million, with a median of $185.7 million in 2023.
  • Per our database at Business Quant, Sarepta Therapeutics' Change in Receivables slumped by 74.99% in 2020 and then spiked by 393.74% in 2021.
  • Over the past 5 years, Sarepta Therapeutics' Change in Receivables (Yearly) stood at $10.5 million in 2020, then soared by 393.74% to $51.6 million in 2021, then rose by 19.34% to $61.6 million in 2022, then spiked by 201.27% to $185.7 million in 2023, then climbed by 8.60% to $201.7 million in 2024.